Combinatorial androgen deprivation with an androgen receptor vaccine

Abstract

It is disclosed herein methods of treating prostate cancer comprising administering to the subject the combination of androgen deprivation therapy (ADT) and a vaccine directed against the androgen receptor or a fragment of the androgen receptor. Also disclosed are methods of increasing the efficacy of androgen deprivation therapy in a subject with prostate cancer comprising administering to the subject an effective amount of a vaccine against the androgen receptor or fragments thereof wherein the method inhibits, delays or reduces the growth of the prostate cancer and/or the development of castration-resistant prostate cancer.

We claim: 
     
         1 . A method of eliciting an anti-tumor response in a subject having prostate cancer comprising:
 a. administering to the subject androgen deprivation therapy (ADT); and   b. administering to the subject a recombinant DNA vaccine comprising a polynucleotide operably linked to a transcriptional regulatory element wherein the polynucleotide encodes a androgen receptor or a fragment of the androgen receptor,   
       wherein the recombinant DNA vaccine is administered in an amount effective to elicit an increased anti-tumor response to the prostate cancer, wherein the combination treatment of ADT and the recombinant DNA vaccine inhibits, delays or reduces the growth of the prostate cancer. 
     
     
         2 . The method of  claim 1 , wherein the DNA vaccine comprises the polynucleotide that encodes a fragment of the androgen receptor ligand binding fragment. 
     
     
         3 . The method of  claim 1 , wherein the DNA vaccine is administered every two weeks to every three months. 
     
     
         4 . The method of  claim 1 , wherein the DNA vaccine is administered biweekly for about 6 to about 10 weeks and subsequently administered quarterly for at least a year. 
     
     
         5 . The method of  claim 1 , wherein the vaccine is administered in a dosage of about 10 mcg to 1 mg. 
     
     
         6 . The method of  claim 1 , wherein the ADT and recombinant vaccine are administered co-currently. 
     
     
         7 . The method of  claim 1 , wherein the ADT is administered before administering the recombinant vaccine. 
     
     
         8 . The method of  claim 1 , wherein the ADT is administered after administering at least one dosage of the recombinant vaccine. 
     
     
         9 . The method of  claim 1 , wherein the androgen deprivation therapy comprises administering an effective amount of at least one androgen receptor-pathway targeting drug selected from the group consisting of LHRH (or GnRH) analogues, LHRH (or GnRH) antagonists, AR antagonists, androgen synthesis inhibitors, an AR degrader and combinations thereof. 
     
     
         10 . The method of  claim 1 , wherein the DNA vaccine is administered intradermally, intramuscularly, subcutaneously, intravenously or intra-arterially, with or without electroporation. 
     
     
         11 . The method of  claim 1 , wherein the DNA vaccine comprises pTVG-ARLBD. 
     
     
         12 . The method of  claim 1 , wherein the DNA vaccine comprises a polynucleotide selected from the group consisting of (i) a mammalian androgen receptor, (ii) a fragment of the androgen receptor that comprises a ligand-binding domain, (iii) a fragment of the ligand-binding domain defined by SEQ ID NO:9, (iv) a fragment of the ligand-binding domain defined by SEQ ID NO:10, (v) a fragment of the ligand-binding domain defined by SEQ ID NO:11, and (vi) a fragment of the ligand-binding domain defined by SEQ ID NO:12, whereby the DNA vaccine elicits an immune response in the subject against the androgen receptor. 
     
     
         13 . The method of  claim 1 , wherein the method further comprises administering to the subject an effective amount of a PD-pathway inhibitor. 
     
     
         14 . A method of increasing the efficacy of androgen deprivation therapy in a subject with prostate cancer comprising administering to the subject an effective amount of a recombinant DNA vaccine comprising a polynucleotide operably linked to a transcriptional regulatory element wherein the polynucleotide encodes a androgen receptor or a fragment of the androgen receptor, wherein the method inhibits, delays or reduces the growth of the prostate cancer. 
     
     
         15 . The method of  claim 14 , wherein the DNA vaccine comprises pTVG-ARLBD. 
     
     
         16 . The method of  claim 14 , wherein the DNA vaccine comprises a polynucleotide selected from the group consisting of (i) a mammalian androgen receptor, (ii) a fragment of the androgen receptor that comprises a ligand-binding domain, (iii) a fragment of the ligand-binding domain defined by SEQ ID NO:9, (iv) a fragment of the ligand-binding domain defined by SEQ ID NO:10, (v) a fragment of the ligand-binding domain defined by SEQ ID NO: 11, and (vi) a fragment of the ligand-binding domain defined by SEQ ID NO:12, whereby the DNA vaccine elicits an immune reaction in the subject against the androgen receptor. 
     
     
         17 . The method of  claim 14 , wherein the method further comprises administering to the subject an effective amount of a PD-pathway inhibitor. 
     
     
         18 . The method of  claim 17 , wherein the PD-pathway inhibitor is an anti-PD-1 blocking antibody or an anti-PD-L1 antibody. 
     
     
         19 . The method of  claim 14 , wherein the prostate cancer is recurrent or metastatic prostate cancer. 
     
     
         20 . The method of  claim 14 , wherein the prostate cancer is castration resistant prostate cancer (mCRPC). 
     
     
         21 . The method of  claim 14 , wherein the prostate cancer is newly diagnosed prostate cancer.